Mdxhealth (MDXH) Q1 2026 earnings review
Sudden Pivot: UTI Exit Slashes Guidance and Hits Profitability
Mdxhealth abruptly shut down its Resolve UTI business due to a Medicare reimbursement reversal, triggering a $10.4M potential recoupment liability and a massive guidance cut. The 'Focus, Execution, and Growth' narrative from prior quarters hit a wall: Q1 Adjusted EBITDA losses tripled YoY to $4.3M, and core Tissue-based test volumes unexpectedly shrank 12%. With pro-forma cash down to $28.2M after an April earnout payment, management's previous promise of 10% EBITDA margins exiting 2026 looks highly vulnerable.
🐂 Bull Case
Exiting the Resolve UTI business eliminates a major source of unpredictability. Pro-forma core revenue (excluding Resolve) still grew 11% YoY to $23.9M, allowing the sales force to focus entirely on the higher-value prostate cancer portfolio.
The company is advancing its PROTECT trial with Oxford University, specifically incorporating AI-enhanced endpoints to improve the prognostic value of its GPS test, positioning it for long-term clinical integration.
🐻 Bear Case
Just one quarter after guiding for $137-$140M in 2026 revenue, management reset the bar to $110-$115M (core cancer only). This erases all anticipated top-line leverage for the year.
Tissue-based tests—the supposed high-margin anchor of the business—saw volumes drop 12% YoY, severely contradicting management's prior claims of a 'sticky' and highly productive commercial channel.
⚖️ Verdict: 🔴
Bearish. The sudden exit of a major product line, shrinking core volumes, and deteriorating margins severely damage the previous quarter's flawless execution narrative. Restructuring costs and a $10.4M Medicare recoupment overhang add substantial near-term risk.
Key Themes
Resolve UTI Shutdown and Recoupment Risk
A massive red flag: Mdxhealth is discontinuing its Resolve UTI offering and shutting down its Plano, Texas lab following an unexplained policy reversal by Medicare administrator Novitas. Worse, Novitas has issued a $10.4M recoupment demand for historical claims. While management is appealing, the impending restructuring charges (severance, lease acceleration, PP&E impairment) will drag on cash flows precisely when the company needs capital to fund its core operations.
Tissue-Based Volume Collapse
Reversing trend. Tissue-based test volumes (Confirm and GPS) fell 12% YoY to 11,110. This is alarming because just a year ago (25Q1), tissue volumes grew 41% YoY, and management explicitly called this segment the primary growth engine driven by a 'best-in-class' sales force. A double-digit contraction here suggests either severe distraction from the ExoDx integration or market share losses to competitors.
Margin Deterioration Accelerates
Gross margin decelerated to 60.7%, a sharp drop from 63.8% a year ago and 65.2% in 25Q3. This was driven by test mix and the ExoDx acquisition overhead. Simultaneously, operating expenses surged 19% to $23.9M. The combination of lower margins and higher OpEx completely derailed the company's path to profitability, turning a $1.0M positive Adjusted EBITDA in 25Q3 into a $4.3M loss this quarter.
AI Platform Integration and PROTECT Trial
To reset the narrative, management is leaning heavily into Artificial Intelligence. The company initiated an AI-dedicated strategic initiative to leverage hundreds of thousands of biopsy tissue specimens. Most notably, the landmark PROTECT trial with Oxford University now includes AI-enhanced endpoints designed to improve the prognostic value of the GPS test, shifting the product from a static biomarker to a dynamic data platform.
Other KPIs
Accelerating/Stable. Excluding the discontinued Resolve business, core cancer revenue grew 11% YoY. This is the true baseline for the company moving forward, stripping away the artificial volume boost and reimbursement noise that Resolve created.
While reported Q1 cash was $43.2M, the company paid a massive $15.0M earnout to Exact Sciences on April 15. Given the return to heavy cash burn (Operating loss of $7.3M in Q1) and upcoming restructuring charges for the Texas lab closure, liquidity is becoming a concern.
Accelerating on paper (up 128% YoY), but this metric is now effectively a dead end. The surge was largely driven by Resolve UTI tests and ExoDx integration. With Resolve shut down, investors should expect this volume number to plummet in Q2.
Guidance
Decelerating aggressively. Management completely abandoned its prior $137-$140M total revenue guidance, establishing a new baseline that excludes Resolve. While they frame this as 20-26% YoY growth over 2025's core business, on an absolute dollar basis, the company will generate roughly the same total revenue in 2026 as it did in 2025 ($107.9M).
Key Questions
Tissue Volume Contraction Drivers
Tissue-based volumes fell 12% YoY after growing robustly in early 2025. How much of this decline is due to sales force distraction from the ExoDx integration versus genuine market share loss or lower biopsy volumes?
Recoupment Liability Funding
If the appeal regarding the $10.4M Novitas recoupment demand fails, how does the company plan to fund this liability, given the current pro-forma cash balance of $28.2M and returning operating cash burn?
EBITDA Margin Targets
In prior quarters, you confidently guided to a 10% Adjusted EBITDA margin exiting 2026. Given the massive guidance cut, gross margin compression, and upcoming restructuring charges, is this target officially off the table?